Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases

NCT05207904 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Squamous Lung Cancer
Brain Metastases

Interventions

DRUG: Tislelizumab, paclitaxel, Carboplatin

Sponsor

Sun Yat-sen University